Rifaximin
Rifaximin is a rifampicin derivative with weaker absorption kinetics; it inhibits DNA-dependent RNA polymerase. Rifaximin is an ansamycin antibacterial compound that is clinically used to treat small intestinal bacterial overgrowth in subjects with inflammatory bowel syndrome (IBS).
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18959249
| Cas No. |
80621-81-4 |
|---|---|
| Purity |
≥98% |
| Formula |
C43H51N3O11 |
| Formula Wt. |
785.88 |
| Chemical Name |
[2S-(2R*,16Z,18E,20R*,21R*,22S*,23S*,24S*,25R*,26S*,27R*,28E)]-25-(Acetyloxy)-5,6,21,23-tetrahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-2,7- [epoxypentadeca(1,11,13)trienimino]-benzofuro[4,5-e]- pyridol[1,2-a]benzimidazole-1,15(2H)-dione |
| Synonym |
Rifacol; XIFAXAN; Fatroximin; Normix; Rifacol |
| Melting Point |
200-205°C (dec) |
| Solubility |
Soluble in alcohols, ethyl acetate, chloroform or toluene. |
| Appearance |
A Red Orange Powder |
Huhulescu S, Sagel U, Fiedler A, et al. Rifaximin disc diffusion test for in vitro susceptibility testing of Clostridium difficile. J Med Microbiol. 2011 Aug;60(Pt 8):1206-12. PMID: 21292853.
Majewski M, McCallum RW. Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial. Adv Med Sci. 2007;52:139-42. PMID: 18217406.
